Centre for Cancer Research Special Seminar: "'Update on Hemophagocytic Lymphohistiocytosis (HLH) and Association to Infections, Maignancies and Rheumatic Disorders", 11 October

Wednesday 11 October, 1.30-2.30pm

Dr Jan-Inge Henter
Karolinsky Institute, Stockholm
Professor of Paediatric Hematology and Oncology

Prof Henter earned an MD from Uppsala University 1980 and after internship in Uppsala completed a fellowship in Pediatrics (1987) in Stockholm. Following this, Prof Henter defended his PhD-thesis at Karolinska Institute in 1990, with focus on hemophagocytic lymphohistiocytosis (HLH). A clinical specialist in Pediatric Hematology and Oncology, he became Professor at Karolinska Institutet in 2004, and Director of Research and Education at Karolinska University Hospital in 2012.

Prof Henter’s main research interest is within the histiocytic disorders, including Hemophagocytic Lymphohistiocytosis (HLH) and Langerhans cell histiocytosis (LCH). In addition to developing the first diagnostic criteria for HLH, PI of HLH-94 as well as HLH-2004, Prof Henter investigates underlying biological and genetic defects in HLH.

Additionally, Prof Henter is interested in clinical and biological studies of Langerhans cell histiocytosis (LCH), with the ultimate aim to reduce morbidity and mortality.
Prof Henter was the President of the Histiocyte Society 2004-2007, and the Founding President of the International Conference for Rare Diseases and Orphan Drugs (ICORD).